User login
Key clinical point: Patients with rheumatoid arthritis (RA) who were treated with Janus kinase (JAK) inhibitor showed reduced humoral response following 2 doses of BNT162b2 COVID-19 vaccine compared with healthy individuals.
Major finding: Patients with RA treated with JAK inhibitors had significantly lower levels of anti-spike immunoglobulin G antibodies (P = .024) than healthy individuals.
Study details: This study involved 12 adult patients with RA treated with JAK inhibitors and 26 healthy individuals who received 2 doses of the BNT162b2 COVID-19 vaccine.
Disclosures: This work was funded by the ISF Corona grant. The authors declared no conflict of interests.
Source: Iancovici L et al. Rheumatology (Oxford). 2021:keab879 (Nov 25). Doi: 10.1093/rheumatology/keab879.
Key clinical point: Patients with rheumatoid arthritis (RA) who were treated with Janus kinase (JAK) inhibitor showed reduced humoral response following 2 doses of BNT162b2 COVID-19 vaccine compared with healthy individuals.
Major finding: Patients with RA treated with JAK inhibitors had significantly lower levels of anti-spike immunoglobulin G antibodies (P = .024) than healthy individuals.
Study details: This study involved 12 adult patients with RA treated with JAK inhibitors and 26 healthy individuals who received 2 doses of the BNT162b2 COVID-19 vaccine.
Disclosures: This work was funded by the ISF Corona grant. The authors declared no conflict of interests.
Source: Iancovici L et al. Rheumatology (Oxford). 2021:keab879 (Nov 25). Doi: 10.1093/rheumatology/keab879.
Key clinical point: Patients with rheumatoid arthritis (RA) who were treated with Janus kinase (JAK) inhibitor showed reduced humoral response following 2 doses of BNT162b2 COVID-19 vaccine compared with healthy individuals.
Major finding: Patients with RA treated with JAK inhibitors had significantly lower levels of anti-spike immunoglobulin G antibodies (P = .024) than healthy individuals.
Study details: This study involved 12 adult patients with RA treated with JAK inhibitors and 26 healthy individuals who received 2 doses of the BNT162b2 COVID-19 vaccine.
Disclosures: This work was funded by the ISF Corona grant. The authors declared no conflict of interests.
Source: Iancovici L et al. Rheumatology (Oxford). 2021:keab879 (Nov 25). Doi: 10.1093/rheumatology/keab879.